Innovent waxay iskaashi la samayn doontaa NeoCura ee Shiinaha si ay u qiimeeyaan badbaadada, farmasokinetics, pharmacodynamics iyo waxtarka hordhaca ah ee daaweynta isku dhafka ah iyadoo la adeegsanayo sintilimab ka Innovent iyo NEO_PLIN2101 oo ka socda NeoCura ee bukaannada kansarka, si loo hormariyo horumarinta kiliinikada isku dhafka immunotherapy ee burooyinka adag ee badan Codsiga Dawada Cusub ee Baarista (IND) ee Maamulka Alaabooyinka Caafimaadka Qaranka (NMPA) mustaqbalka dhow.
Dr. Liu Yongjun, Madaxweynaha Innovent, ayaa yiri: "Waxaan aad ula dhacsanahay NeoCura's dhuunta R & D ee kala duwan iyo kooxda cilmi-baarista caalamiga ah, waxaanan ku faraxsanahay inaan galno iskaashigan istaraatiijiyadeed si aan u sahamino qiimaha kiliinikada ee sintilimab oo ay weheliso tallaalada neoantigen ee burooyinka adag . Innovent waxay leedahay dhuumo adag oo awood u leh xagga difaaca jirka iyo bayoolajiga kansarka. Hadda, waxaanu haynaa shan dawooyin cusub oo la ansixiyey oo laga bilaabay Shiinaha waxaanan yeelan doonaa in ka badan 10 dawooyin cusub oo la bilaabayo 2-3 sano ee soo socota. Qalabkayaga si buuxda isku dhafan ayaa urursaday R&D xooggan, kobcinta kiliinikada iyo awoodaha ganacsi waxayna ku habboon tahay la-hawlgalayaasha gudaha iyo dibedda. Waxaan sidoo kale rajeyneynaa inaan sii sahamno fursadaha cusub ee ballaarinta calaamadaha iyo kor u qaadista waxtarka daaweynta sintilimab oo ay weheliso daawaynta cusub. Waxaan rajaynaynaa wada shaqayn balaadhan oo qoto dheer oo dhex marta labada dhinac mustaqbalka. "
Dr. Wang Yi, aasaasaha NeoCura, wuxuu yiri: "Waqtigan xaadirka ah, tallaalada neoantigen waa hab kacaan oo daweyn ah oo soo baxaya adduunka oo dhan. NeoCura waxa ay diiradda saareysay R&D ee tallaallada neoantigen ee burooyinka tan iyo markii la aasaasay, iyadoo rajeyneysa in ay ka gudubto caqabadaha jira daweynta difaaca jirka ee daaweynta burooyinka adag iyada oo loo marayo adeegsiga tignoolajiyada cusub. Wadashaqeynta Innovent waxay ka ciyaari doontaa doorka isdhexgalka ee tallaalada neoantigen ee shakhsi ahaaneed iyo daawooyinka monoclonal antibody waxayna si wadajir ah u sahamiyaan saameynta kiliinikada ee daaweynta isku dhafka ah ee daaweynta burooyinka adag, taas oo la filayo inay wanaajiso heerka jawaabta ujeedada kansarka immunotherapy iyo keeni fursado cusub. loogu talagalay hababka isku dhafka ah ee kansarka."
MAXAA LAGU QAADAYAA MAQAALKAN:
- Innovent waxay iskaashi la samayn doontaa NeoCura ee Shiinaha si ay u qiimeeyaan badbaadada, farmasokinetics, pharmacodynamics iyo waxtarka hordhaca ah ee daaweynta isku dhafka ah iyadoo la adeegsanayo sintilimab ka Innovent iyo NEO_PLIN2101 oo ka socda NeoCura ee bukaannada kansarka, si loo hormariyo horumarinta kiliinikada isku dhafka immunotherapy ee burooyinka adag ee badan Codsiga Dawada Cusub ee Baarista (IND) ee Maamulka Alaabooyinka Caafimaadka Qaranka (NMPA) mustaqbalka dhow.
- The collaboration with Innovent will play a synergistic role of personalized neoantigen vaccines and monoclonal antibody drugs and jointly explore the clinical effect of the combination therapy in the treatment of solid tumors, which is expected to improve the objective response rate of cancer immunotherapy and bring new opportunities for cancer combination regimens.
- NeoCura has been focusing on the R&D of tumor neoantigen vaccines since its establishment, hoping to overcome the challenges of existing immunotherapy in the treatment of solid tumors through the application of new technologies.
